The shot — for now called mRNA-1083 — "has met its primary endpoints, eliciting a higher immune response than the licensed comparatorThe phase 3 trial is only another step towards approval of the dual-purpose shot, which won't be okayed in time for this years'on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses," Moderna CEO Stéphane Bancel said...
In a trial involving more than 4,000 adults ages 65 or older, the mRNA-1083 vaccine triggered immune responses to three influenza variants as well as to theSimilar results were also seen in another group of about 4,000 people between 50 and 64 years of age, Moderna said. The trial was "blinded," meaning that neither the patients nor the people conducting the trial knew who got which
The new findings have not yet been peer-reviewed, although Moderna said it plans to submit the trial results for publication and to possible review by the U.S. Food and Drug Administration . The real issue is whether vaccine-fatigued Americans will avail themselves of the dual-purpose vaccine, should it become available, said Sue Peschin, president and CEO of the non-profit Alliance forPrevention, then that's better for everyone because it helps protect everyone in the community,” Peschin said. “We would love to see the combination vaccines come to market if the FDA deems them safe and effective.